GlassScriptPhysician profile
Ruth Ann Mazo
NPI 1568638666
$833.54
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $179 · 2021: $314 · 2022: $233.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $400.66 | 2020-2022 | |
| Abbvie INC. | $99.11 | 2020-2022 | |
| Allergan, INC. | $74.80 | 2019-2022 | |
| Medtronic USA, INC. | $40.84 | 2019-2020 | |
| Janssen Biotech, INC. | $39.72 | 2019 | |
| Axonics, INC. | $37.90 | 2021 | |
| Medtronic, INC. | $26.13 | 2022 | |
| Pfizer INC. | $25.83 | 2019 | |
| Coloplast Corp | $23.75 | 2021 | |
| Boston Scientific Corporation | $19.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2022 | |
| Amgen INC. | $11.74 | 2021 | |
| Travere Therapeutics, INC. | $3.80 | 2019-2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Mazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.